Home  |  Contact

Cellosaurus WM164 (CVCL_7928)

Cell line name WM164
Synonyms WM-164; WM 164
Accession CVCL_7928
Resource Identification Initiative To cite this cell line use: WM164 (RRID:CVCL_7928)
Comments Part of: Wistar Institute melanoma cell line collection.
Doubling time: 48 hours (PubMed=2253310).
Omics: Deep proteome analysis.
Omics: Transcriptome analysis.
Caution: The reported STR profile from Wistar of this cell line was changed at one point between February 2016 when we retrieved them and entered them in the Cellosaurus and May 2018. The major changes were: CSF1PO: 11,12->12, D18S51: 12,21->10,12,13, D2S1338: 19->18,19, D5S818: 11,12->12, FGA: 20->21,25 and vWA: 14,15->14,18.
Sequence variations Heterozygous for BRAF p.Val600Glu (c.1799T>A) (PubMed=18632627; Wistar).
Disease Melanoma (NCIt: C3224)
Derived from metastatic site: Lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_6357 (451Lu)
Originate from same individual CVCL_DG51 ! Mel1617
Sex of cell Male
Age at sampling 22Y
Category Cancer cell line
STR profile Source(s): Wistar

Web pages https://www.wistar.org/our-scientists/meenhard-herlyn

PubMed=2918552; DOI=10.1093/jnci/81.6.440
Iliopoulos D., Ernst C., Steplewski Z., Jambrosic J.A., Rodeck U., Herlyn M., Clark W.H. Jr., Koprowski H., Herlyn D.
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides.
J. Natl. Cancer Inst. 81:440-444(1989)

Herlyn D., Iliopoulos D., Jensen P.J., Parmiter A., Baird J., Hotta H., Adachi K., Ross A.H., Jambrosic J.A., Koprowski H., Herlyn M.
In vitro properties of human melanoma cells metastatic in nude mice.
Cancer Res. 50:2296-2302(1990)

PubMed=2253310; DOI=10.1007/BF00046337
Herlyn M.
Human melanoma: development and progression.
Cancer Metastasis Rev. 9:101-112(1990)

Juhasz I., Albelda S.M., Elder D.E., Murphy G.F., Adachi K., Herlyn D., Valyi-Nagy I.T., Herlyn M.
Growth and invasion of human melanomas in human skin grafted to immunodeficient mice.
Am. J. Pathol. 143:528-537(1993)

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=16827748; DOI=10.1111/j.1600-0749.2006.00322.x
Hoek K.S., Schlegel N.C., Brafford P., Sucker A., Ugurel S., Kumar R., Weber B.L., Nathanson K.L., Phillips D.J., Herlyn M., Schadendorf D., Dummer R.
Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
Pigment Cell Res. 19:290-302(2006)

PubMed=18632627; DOI=10.1158/0008-5472.CAN-08-0235
Smalley K.S.M., Contractor R., Nguyen T.K., Xiao M., Edwards R., Muthusamy V., King A.J., Flaherty K.T., Bosenberg M., Herlyn M., Nathanson K.L.
Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression.
Cancer Res. 68:5743-5752(2008)

PubMed=18790768; DOI=10.1158/1535-7163.MCT-08-0431
Smalley K.S.M., Lioni M., Dalla Palma M., Xiao M., Desai B., Egyhazi S., Hansson J., Wu H., King A.J., Van Belle P., Elder D.E., Flaherty K.T., Herlyn M., Nathanson K.L.
Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas.
Mol. Cancer Ther. 7:2876-2883(2008)

Gene expression databases GEO; GSM109030
GEO; GSM186471
GEO; GSM186472
GEO; GSM952584
Other Wikidata; Q54994187
Polymorphism and mutation databases Cosmic; 888857
Cosmic; 897481
Cosmic; 928684
Cosmic; 1155550
Cosmic; 1187586
Cosmic; 1303065
Proteomic databases PRIDE; PXD004343